IL6 and leukemia: IL-6 promotes relapse in AML paediatric patients via supporting the leukaemia stem cells (LSCs) through inducing a STAT3 downstream signalling, that might enhance the survival and expansion of LSCs in the initial rounds of chemotherapy; thus, disease relapse occurs [7, 10].